21 May 2013
Keywords: supergen, nipent, shows, promise, non-hodgkin, lymphoma, usa
Article | 21 July 2003
SuperGen of the USA says that data from a 30-patient Phase II study suggest that its Nipent (pentostatin for injection), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 July 2003
28 July 2003
20 May 2013
© 2013 thepharmaletter.com